Literature DB >> 2820284

Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease.

J T Zakrzewski, N C Barnes, J F Costello, P J Piper.   

Abstract

In order to investigate the possible role of arachidonic acid metabolites as lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease (COPD), sputum from patients with cystic fibrosis, chronic bronchitis, or bronchiectasis was analyzed for various eicosanoids using a combination of radioimmunoassay and bioassay. Leukotriene (LT) B4, cysteinyl-containing LTs, and prostaglandins (PGs) E2, F2 alpha, 6-oxo-PGF1 alpha, and thromboxane B2 were found in all sputum samples. Saliva, which can contaminate sputum, contained low concentrations of prostanoids but not LTs. Inflammatory cells, including polymorphonuclear leukocytes (PMNs) are present in sputum. Because LTB4 generated by these cells is chemotactic for PMNs, it is suggested that this dihydroxy acid contributes to the inflammation of cystic fibrosis and other diseases characterized by airway obstruction. The source of the cysteinyl-containing LTs is less clear; these LTs may constrict respiratory smooth muscle and/or stimulate mucus formation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2820284     DOI: 10.1164/ajrccm/136.3.779

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  23 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 3.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 4.  New therapies for chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

5.  Leukotriene B4 and asthma.

Authors:  P E Christie; N C Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

Review 6.  Leukotriene receptor antagonists: clinical effects.

Authors:  N Barnes
Journal:  J R Soc Med       Date:  1997-04       Impact factor: 5.344

Review 7.  The role of inflammation in the pathophysiology of CF lung disease.

Authors:  James F Chmiel; Melvin Berger; Michael W Konstan
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion.

Authors:  D C Devor; B D Schultz
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

9.  Exhaled leukotrienes and prostaglandins in COPD.

Authors:  P Montuschi; S A Kharitonov; G Ciabattoni; P J Barnes
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

10.  Cif is negatively regulated by the TetR family repressor CifR.

Authors:  Daniel P MacEachran; Bruce A Stanton; George A O'Toole
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.